|
Vaccine Detail
HIV DNA vaccine pHIS-SHIV-B |
Vaccine Information |
- Vaccine Name: HIV DNA vaccine pHIS-SHIV-B
- Target Pathogen: Human Immunodeficiency Virus
- Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
- Vaccine Ontology ID: VO_0004348
- Type: DNA vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Monkey
- Antigen: full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004)
- env
gene engineering:
- Type: DNA vaccine construction
- Description: The DNA vaccine strain, pHIS-SHIV-B, encoded full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004).
- Detailed Gene Information: Click Here.
- Gag protein from SIV-mnd 2
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- Pol SIV
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- Tat
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- rev from HIV 1
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- vpu
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- DNA vaccine plasmid: pHIS64 DNA vaccine plasmid
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Macaque Response
- Vaccine Immune Response Type: VO_0000286
- Efficacy: DNA vaccination alone primed for protection almost as effectively as the DNA/fowlpox virus regimen (Dale et al., 2004).
- Host IFNG from Macaca nemestrina response
- Description: SIV Gag-specific CD8 T cells expressing IFN-γ were dramatically boosted after challenge. Mean Gag-specific CD8 T cells peaked 3 weeks following challenge at 11.7% of all CD8 T cells in these outbred pigtail macaques immunized with the 2DNA/FPV regimen. The other vaccine groups had lower mean postchallenge CD8 T-cell responses, with peak responses at week 2 following challenge numbering 3.8% in the 3DNA group, 1.1% responses in the 1DNA/FPV group, and 2.0% in the 2DNA/FPV-IFN-γ-immunized animals (Dale et al., 2004).
- Detailed Gene Information: Click Here.
|
References |
Dale et al., 2004: Dale CJ, De Rose R, Stratov I, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Kent SJ. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. Journal of virology. 2004; 78(24); 13819-13828. [PubMed: 15564490].
|
|